高危皮肤鳞状细胞癌单纯莫氏手术治疗后的临床结局:局部复发、区域淋巴结转移、无进展生存与疾病特异性死亡分析
该回顾性研究纳入2000年1月1日至2020年1月1日期间在两所大学附属私立莫氏手术转诊中心治疗的高危原发性皮肤鳞状细胞癌,共527例患者的581个肿瘤,获得579个肿瘤的随访数据。5年疾病特异性生存率为95.7%,5年无局部复发生存率为96.9%,区域无淋巴结转移生存率为93.8%,远处无转移生存率为97.3%,5年和10年无转移进展生存率分别为92.6%和90.0%。作者认为,莫氏手术相比历史wide local excision对照可带来疾病特异性生存优势。
要点
- 581个高危原发性皮肤鳞状细胞癌中,5年疾病特异性生存率为95.7%,平均生存时间18.6年。
- 5年无局部复发生存率96.9%,区域无淋巴结转移生存率93.8%,远处无转移生存率97.3%。
- 发生区域淋巴结转移并接受挽救性头颈清扫(伴或不伴放疗)者,2年疾病特异性生存率为90.5%。
核心结论
- 该队列是迄今接受莫氏手术治疗的最大高危皮肤鳞状细胞癌队列,其局部复发、淋巴结转移和疾病特异性死亡率低于使用Brigham and Women's Hospital和美国癌症联合委员会第八版分期系统的历史参照对照所报告的率。
- 作者表明,莫氏手术相比历史wide local excision为高危肿瘤带来疾病特异性生存优势。
- 作者认为,莫氏手术通过改善局部肿瘤控制似乎可降低区域转移性疾病的发生频率,并可能即使对发生区域转移的患者也带来生存优势。
研究设计与样本
- 回顾性综述,纳入2000年1月1日至2020年1月1日期间在两所大学附属私立莫氏手术转诊中心治疗的所有高危皮肤鳞状细胞癌,随访至2020年4月1日。
- 共识别527例患者的581个高危原发性皮肤鳞状细胞癌,其中获得579个肿瘤的随访数据。
主要发现
- 5年疾病特异性生存率为95.7%,平均生存时间18.6年。
- 5年无局部复发生存率为96.9%,区域无淋巴结转移生存率为93.8%,远处无转移生存率为97.3%。
- 5年和10年无转移进展生存率分别为92.6%和90.0%。
- 发生区域淋巴结转移并接受挽救性头颈清扫伴或不伴放疗的患者,2年疾病特异性生存率为90.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of cutaneous squamous cell carcinoma (cSCC) continues to increase, and it is now predicted that the number of deaths from cSCC will surpass that of melanoma within the next 5 years. Although most cSCCs are successfully treated, there exists an important subset of high-risk tumors that have the highest propensity for local recurrence (LR), nodal metastasis (NM), and disease-specific death (DSD). OBJECTIVE: We investigated the clinical outcomes of high-risk cSCCs treated with Mohs surgery (MS) alone, analyzing LR, NM, distant metastasis, and DSD. In addition, we analyzed progression-free survival and DSD in patients who underwent salvage head/neck dissection for regional NMs. METHODS: Retrospective review of all high-risk cSCC treated in our clinics between January 1, 2000, and January 1, 2020, with follow-up through April 1, 2020. SETTING: Two university-affiliated, private-practice MS referral centers. RESULTS: In total, 581 high-risk primary cSCCs were identified in 527 patients, of which follow-up data were obtained for 579 tumors. The 5-year disease-specific survival was 95.7%, with a mean survival time of 18.6 years. The 5-year LR-free survival was 96.9%, the regional NM-free survival was 93.8%, and the distant metastasis-free survival was 97.3%. The 5- and 10-year progression-free survival rates from metastatic disease were 92.6 and 90.0%, respectively. In patients who experienced regional NMs and underwent salvage head and neck dissection with or without radiation, the 2-year disease-specific survival was 90.5%. CONCLUSION: Our cohort, which is the largest high-risk cSCC cohort treated with MS to date, experienced lower rates of LR, NM, and DSD than those reported with historical reference controls using both the Brigham and Women's Hospital and American Joint Committee on Cancer, Eighth Edition, staging systems. We demonstrated that MS confers a disease-specific survival advantage over historical wide local excision for high-risk tumors. Moreover, by improving local tumor control, MS appears to reduce the frequency of regional metastatic disease and may confer a survival advantage even for patients who develop regional metastases.
引用
- Soleymani T, Brodland DG, Arzeno J, et al. Clinical outcomes of high-risk cutaneous squamous cell carcinomas treated with Mohs surgery alone: An analysis of local recurrence, regional nodal metastases, progression-free survival, and disease-specific death. J Am Acad Dermatol. 2022. PMID: 35760236. doi:10.1016/j.jaad.2022.06.1169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。